-- 加拿大皇家銀行資本市場（RBC Capital Markets）週五在一份報告中指出，GoDaddy (GDDY) 第一季度業績“非常穩健”，並重申了全年展望，儘管該股目前的股價可能更多地反映了業績指引下調的預期。 報告指出，第一季亮點包括應用程式與商務業務的訂單成長放緩至9%，符合預期，此前該業務曾進行過折扣促銷。 報告指出：「折扣促銷仍在繼續，但保持穩定。考慮到人工智慧領域的擔憂， 如果該股想要繼續走強，應用程式與商務業務必須至少保持與上季相同的成長率。 」 報告也指出，利潤率表現超乎預期，使得今年剩餘時間的業績看起來相當輕鬆。 加拿大皇家銀行維持對GoDaddy的「跑贏大盤」評級，目標價為95美元。
Price: $86.93, Change: $+0.13, Percent Change: +0.16%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $1 to $67, 26.1x our 2026 EPS estimate (up $0.08 to $2.57; 2027 estimate up $0.06 to $3.05), below DXCM's one-year historical forward average of 34.2x and well below the three-year average of 56.6x, to reflect stronger competition within the continuous glucose monitoring space and uncertain insurance coverage and rebate dynamics, in our view. DXCM recently launched the G7 15-day continuous glucose monitoring (CGM) system in the U.S., which offers users a longer-wear time between devices and increased accuracy, per DXCM. The company expects close to half of its U.S. base to convert to the new device by year-end 2025. We think the addressable market for DXCM is large and far from saturated, but a slower sales growth rate is a concern, which we attribute to market share losses and slow progress in gaining additional insurance coverage approvals.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target of $211, up $5, reflects EV/EBITDA and DCF analyses. We apply an 8.0x multiple of EV to projected 2027 EBITDA, above CVX's historical forward average, but below peak levels, yielding $186 per share. Our DCF model, using FCF growth of 7.1% per year for 10 years and 2.5% thereafter, discounted at 6.0%, yields $237 per share. We cut our 2026 EPS estimate by $0.14 to $11.16 and our 2027 estimate by $0.39 to $8.93. CVX suffered some volume degradation in international upstream in Q1, as the war in the Middle East has disrupted the normal course of business. We note, however, that this degradation was less acute for CVX than for its chief rival, Exxon Mobil (XOM 153 ***). CVX maintained a conservative approach to spending in Q1 despite the ramp in crude prices, as we estimate that its reinvestment rate was just 44% in Q1, about on par with that of XOM at 43%. Shares yield 3.7%, and we see a healthy degree of buyback activity as well.